Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
Key facts
- Who runs it
- Travera Inc
- Where
- Boston, Duarte, and New York, United StatesSee the 4 sites
- Trial code
- Status
- Terminated
- People taking part
- 33 people enrolled
- Started
- 11 Feb 2019
- Ended
- 30 Jun 2024
- Type of study
- Observational, 2 groups
- Record updated
- 3 July 2024
- Why it stopped
- Insufficient pace of enrollment due to changes in MM SOC practices
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Written Informed Consent provided by patient
- MM, with the following conditions:; (CLOSED) *For patients in the Vanguard cohort*
- Treatment naïve disease with BM clinically indicated; *For patients in the RRMM cohort*
- Relapsed/refractory disease with BM samples clinically indicated
- Within 4-weeks prior to initiation of 2nd-line or later therapy
- Patient's oncologist must be planning to change the patient's next line of treatment to a monotherapy or combination therapy composed exclusively of drugs from the following list: Bortezomib (Velcade), Carfilzomib (Kyprolis), Lenalidomide (Revlimid), Pomalidomide (Pomalyst), Cyclophosphamide (Cytoxan), Dexamethasone, Ixazomib (Ninlaro), Venetoclax (Venclexta), Selinexor (Xpovio)
Who cannot take part
- Daratumumab/Elotuzumab or other antibody-based therapeutic regimens as immediately planned treatment (as prior therapy is acceptable)
- Prior exposure to CAR-T therapy
- Prior allogeneic stem cell transplant
- Has received any systemic chemotherapy or RT, including palliative, within 7 days prior to BM biopsy
- Has received any Ab therapy within 4 weeks prior to BM biopsy
- Unable or unwilling to provide informed consent
- Patient enrolled/enrolling in a clinical trial where data or specimen sharing provisions preclude use in this study
Where in United States
- Dana-Farber Cancer InstituteBoston, United States
- Massachusetts General HospitalBoston, United States
- City of Hope Comprehensive Cancer CenterDuarte, United States
- Weill Cornell Medicine | New York-PresbyterianNew York, United States
About the trial
What the trial wants to find out
This study will collect bone marrow (BM) aspirate samples from patients with relapsed refractory multiple myeloma (RRMM) prior to the start of a new treatment regimen for the purposes of prospectively measuring single-cell mass accumulation rate (MAR) as a biomarker of patient response to that regimen.
Read full original descriptionShow less
The primary study objective is to explore whether the single-cell MAR biomarker can predict patient response in RRMM patients. In order to enable this primary objective, two patient cohorts will be required. First, a small vanguard cohort of patients with treatment naïve disease to define drug concentrations used for testing, and second, the main RRMM patient cohort. Data will be collected to estimate the biomarker's predictive properties (accuracy, sensitivity, specificity), and to support improvement of the MAR biomarker through additional research and discovery within the study dataset.
The 2 groups in the trial
- Vanguard
(CLOSED TO ENROLLMENT) Bone marrow (BM) from this cohort of up to 30 treatment naïve subjects with a diagnosis of multiple myeloma (MM) will first be used to define sample processing pipeline performance and optimal drug dosages before sites on the study proceed to mass accumulation rate (MAR) testing of BM from the relapsed/refractory MM (RRMM) subject cohort.
- Relapsed/Refractory MM
BM from this cohort of 100 relapsed subjects with a diagnosis of MM will be used to test the MAR assay's accuracy of condition by matching conditions tested in vitro to the patient's planned course of therapy. This is the main study cohort described in the Eligibility section.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 3 July 2024